Related Experiment Video
Updated: Nov 24, 2025
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Metastatic cutaneous apocrine adenocarcinoma successfully treated with systemic anti-androgen therapy-A case report
Fanny Collette1, Marc Hamoir2, Pascal Van Eeckhout3
1Institut Roi Albert II Department of Medical Oncology Cliniques universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (POLE MIRO) Université catholique de Louvain Brussels Belgium.
Abstract:
Primary cutaneous apocrine adenocarcinoma (PCAC) is an extremely rare neoplasm involving the sweat glands. Due to a lack of cases, there is no consensus for the systemic treatment of locally advanced or metastatic PCAC. Anti-androgen therapy may have activity in inoperable or metastatic PCAC with high androgen receptor (AR) expression.
Insights
Primary cutaneous apocrine adenocarcinoma (PCAC) is a rare cancer. Anti-androgen therapy shows potential for advanced PCAC with high androgen receptor expression.
Area of Science:
- Oncology
- Dermatology
- Endocrinology
Background:
- Primary cutaneous apocrine adenocarcinoma (PCAC) is an exceedingly rare malignancy.
- Limited data exists regarding the systemic treatment of advanced or metastatic PCAC.
- Standard treatment protocols are not established due to the rarity of the disease.
Observation:
- The study focuses on the potential of anti-androgen therapy for PCAC.
- Androgen receptor (AR) expression is a key factor in treatment response.
- Cases of inoperable or metastatic PCAC were considered.
Findings:
- Anti-androgen therapy demonstrated potential activity in managing PCAC.
- High androgen receptor (AR) expression in tumors correlated with potential therapeutic benefit.
- This suggests a targeted approach for specific PCAC subtypes.
Implications:
- Anti-androgen therapy may represent a viable systemic treatment option for advanced PCAC.
- Targeting AR could improve outcomes for patients with high AR-expressing tumors.
- Further research is warranted to confirm efficacy and establish treatment guidelines.
More Related Videos
05:05Generating a Murine Orthotopic Metastatic Breast Cancer Model and Performing Murine Radical Mastectomy
Published on: November 29, 2018
09:48An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019